Renal Cancer
Histone-dependent PARP-1 inhibitors: A novel therapeutic modality for the treatment of prostate and renal cancers.
May 18, 2020
Clinicopathological Significance of MTUS1 Expression in Patients With Renal Cell Carcinoma.
May 15, 2020